Skip to main content
Premium Trial:

Request an Annual Quote

Two Hospitals Collaborate to Assess Axela Breast Cancer Assay

NEW YORK (GenomeWeb News) – Mount Sinai Services in Toronto and Brigham and Women's Hospital in Boston are collaborating to test Axela's Risk of Recurrence Assay, the company said today.

As part of the collaboration, the two hospitals will conduct a blinded trial of breast cancer patients to assess the ability of the assay to predict the five-year risk of distant metastasis and the ability of cancer center laboratories to use the test locally.

The study will provide information on the risk of recurrence, ER/PR/HER2 status, and molecular subtype, as well as information about the activation levels of the proliferation and immune response pathways on formalin-fixed, paraffin-embedded tumor samples analyzed with the Toronto-based firm's Flow-Thru Chip technology. Results of the study are expected to be completed in the fall and will be used to characterize the assay's performance in the context of other clinical factors being used to manage the treatment of breast cancer patients.

Financial and other terms of the collaboration were not disclosed.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.